Search
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … [L41469] On December 17, 2025, the U.S.
Cobicistat
go.drugbank.com/drugs/DB09065ApprovedInvestigationalMore specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 … Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Categories: Antivirals used in combination for the treatment of HIV infections, Metabolic Side Effects of Drugs and SubstancesChlorine
go.drugbank.com/drugs/DB11109ApprovedInvestigationalBeing a yellow-green gas at room temperature, chlorine is the second most abundant halogen on Earth. It is commonly used in sanitation, disinfection and antiseptic processes. … Chlorine is a stongly oxidizing agent and the third most electronegative element which belongs to the group of halogens with the atomic number 17 and symbol Cl.
Categories: Weapons of Mass Destruction, Compounds used in a research, industrial, or household settingVerteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet … oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Categories: Heterocyclic Compounds with 4 or More RingsDiclofenamide
go.drugbank.com/drugs/DB01144ApprovedA carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Categories: combinations of sulfonamidesAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawn[A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113] … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.
Categories: Antivirals for treatment of HCV infectionsCarisoprodol
go.drugbank.com/drugs/DB00395ApprovedIn January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential … for abuse in addition to a low risk of dependence [L5074].
Synonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamateLofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] … Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Drugs Used in Opioid DependenceVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigational[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support … It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions
Sorghum halepense pollen
go.drugbank.com/drugs/DB10365ApprovedSorghum halepense pollen is the pollen of the Sorghum halepense plant. Sorghum halepense pollen is mainly used in allergenic testing.
Mixtures: Mixture of Standardized and Non-Standardized Southern Grasses, Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract